$HALB Halberd Receives Several Strains of Antibiot
Post# of 630
(Total Views: 160)
Posted On: 12/06/2022 8:28:28 AM
$HALB Halberd Receives Several Strains of Antibiotic Resistant Bacteria from CDC to Test Laser Eradication
https://www.accesswire.com/730331/Halberd-Rec...radication
Halberd's method shown previously to be effective on multiple strains of antibiotic resistant bacteria to be tested on CDC strains.
JACKSON CENTER, PA / ACCESSWIRE / December 6, 2022 / Halberd Corporation (OTC PINK:HALB) has received from the CDC (Centers for Disease Control and Prevention) an array of antibiotic resistant bacteria (ARB). Halberd will utilize its laser eradication technology which successfully eradicated numerous Gram-Negative bacteria whose results were reported in an October 18, 2022 press release. Gram-negative bacteria (GNB) are characterized by their high resistance to antibiotics.[1]
The CDC provides various strains of antibiotic resistant bacteria to research organizations to encourage development of methods and means of overcoming/neutralizing the bacteria's resistance to known antibiotics or destroying these bacteria without harming the patient.
Dr. Mitchell S. Felder, Halberd's Chief Technology Officer and a board-certified attending neurologist stated, "Our results to date on E. coli, Salmonella and Shigella have been very encouraging and we are excited to commence testing of our patent-pending methodology on these antibiotic resistant strains from the CDC."
William A. Hartman, Chairman, President & CEO of Halberd Corporation, added, "The importance of the fact that the CDC supplied this material to Halberd Corporation cannot be over-emphasized. Halberd's patented technology could be of intense interest to the government, particularly the military, because of our ability to potentially counteract bio-weapons. We regard this responsibility as important to the potential safety and security of the country and to the interests of the company as well."
https://www.accesswire.com/730331/Halberd-Rec...radication
Halberd's method shown previously to be effective on multiple strains of antibiotic resistant bacteria to be tested on CDC strains.
JACKSON CENTER, PA / ACCESSWIRE / December 6, 2022 / Halberd Corporation (OTC PINK:HALB) has received from the CDC (Centers for Disease Control and Prevention) an array of antibiotic resistant bacteria (ARB). Halberd will utilize its laser eradication technology which successfully eradicated numerous Gram-Negative bacteria whose results were reported in an October 18, 2022 press release. Gram-negative bacteria (GNB) are characterized by their high resistance to antibiotics.[1]
The CDC provides various strains of antibiotic resistant bacteria to research organizations to encourage development of methods and means of overcoming/neutralizing the bacteria's resistance to known antibiotics or destroying these bacteria without harming the patient.
Dr. Mitchell S. Felder, Halberd's Chief Technology Officer and a board-certified attending neurologist stated, "Our results to date on E. coli, Salmonella and Shigella have been very encouraging and we are excited to commence testing of our patent-pending methodology on these antibiotic resistant strains from the CDC."
William A. Hartman, Chairman, President & CEO of Halberd Corporation, added, "The importance of the fact that the CDC supplied this material to Halberd Corporation cannot be over-emphasized. Halberd's patented technology could be of intense interest to the government, particularly the military, because of our ability to potentially counteract bio-weapons. We regard this responsibility as important to the potential safety and security of the country and to the interests of the company as well."
(0)
(0)